Last updated on May 2020

A Study to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged Release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attentiondeficit/Hyperactivity Disorder (ADHD)

Brief description of study

This interventional multicenter dose-optimization Phase IV PASS conducted in Europe and the USA evaluates the comparative long-term safety and efficacy of SPD503 in children and adolescents aged 6 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) for whom stimulants are not suitable, not tolerated, or shown to be ineffective.

The study will be conducted in two parts: Study Part A (randomized, double-blinded, parallel-group, placebo- and active comparator-controlled, 3-treatment arm safety and efficacy evaluation of SPD503) and Study Part B (open label SPD503 treatment).

Detailed Study Description

This study will be conducted in two parts Part A and Part B. Part A is a double-blinded, double-dummy, placebo-controlled study with an atomoxetine arm as an active reference to SPD503. Eligible participants will be randomized in a 1:1:1 ratio among SPD503, atomoxetine, and placebo treatment arms for the first 18 weeks of double-blinded treatment. At the end of the first 18 weeks, participants in the placebo treatment arm will rollover to Part B of the study directly for an additional 52 weeks of open-label SPD503 treatment. Participants in the SPD503 and atomoxetine treatment arms will continue in Part A of the study for the remainder of the 52 weeks. At the end of 52 weeks of double-blinded treatment and evaluation in Part A. Participants in the SPD503 and atomoxetine treatment arms will rollover into Part B of the study for an additional 1 year of open-label SPD503 treatment.

Clinical Study Identifier: NCT04085172

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.